The $2 Billion Handshake That Ends Biotech's Nastiest Patent Fight
Ascendis Pharma and BioMarin just ended an 18-month patent war spanning three continents with a royalty deal that has BioMarin collecting 20% of YUVIWEL's U.S. sales. The settlement removes a major legal cloud, but the competitive chess match in achondroplasia is just getting started.
Two Rare Disease Giants Walk Into a Courtroom
Imagine spending 18 months suing someone across three continents, only to end up writing them a check and shaking their hand. That's basically what just happened between Ascendis Pharma and BioMarin.
On August 30, the two rare disease heavyweights signed a binding term sheet to settle their sprawling global patent war over YUVIWEL (navepegritide), Ascendis's drug for achondroplasia, a form of dwarfism that affects bone growth in children. The deal gives BioMarin a fat royalty stream. It gives Ascendis the legal clarity to actually sell its drug without looking over its shoulder. And it ends one of biotech's most aggressive IP slugfests in recent memory.
Wall Street's verdict was swift: Ascendis dipped slightly. The market saw a winner and a "this is fine" company, and priced accordingly.
But the real story is more interesting than a stock move.
The Fight Behind the Settlement
To understand why this deal matters, you need to know how ugly things got.
BioMarin already had a blockbuster achondroplasia drug called Voxzogo on the market. Voxzogo works by mimicking a molecule called C-type natriuretic peptide (CNP), which helps cartilage cells grow and divide normally in kids whose bones are essentially getting a "stop growing" signal from a hyperactive gene called FGFR3. Think of CNP as the override button that tells bones: "Actually, keep going."
Ascendis built its own CNP-based drug using its proprietary TransCon platform, which is essentially a molecular time-release capsule. It attaches an inert carrier to a known drug so the active ingredient gets released slowly over time. That's how Ascendis turned a daily-injection concept into a once-weekly shot for kids. Pretty compelling pitch to parents.
BioMarin looked at Ascendis's drug and said: "That's our patent territory."
What followed was a litigation blitz. In January 2025, BioMarin sued Ascendis at the Unified Patent Court in Munich, claiming its European CNP patent (confirmed by the European Patent Office in 2024) covered what Ascendis was doing. Then, after Ascendis filed its FDA application on , BioMarin filed a complaint with the U.S. International Trade Commission on . That's the nuclear option in patent disputes; it can block products at the border.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
March 31, 2025
April 1, 2025
Ascendis fired back with a declaratory-judgment lawsuit in federal court 11 days later. The legal ping-pong continued through stays, appeals, and a Federal Circuit ruling in March 2026. Meanwhile, the FDA approved YUVIWEL on February 27, 2026, creating an absurd situation: Ascendis had a drug it could technically sell but couldn't fully commercialize without resolving a patent cloud hanging over it.
What the Deal Actually Says
The binding term sheet lays out a surprisingly clean structure. BioMarin grants Ascendis a non-exclusive, worldwide, transferable, royalty-bearing license to the contested patents. That covers research, development, manufacturing, and sales of YUVIWEL for all indications, including achondroplasia and a related condition called hypochondroplasia.
The price tag? Ascendis pays BioMarin 20% of annual net sales in the United States and 18% of annual net sales in the EU, Brazil, and South Korea. Those royalties kick in retroactively from YUVIWEL's first commercial sale and run until May 2030.
In return, both sides dismiss all pending litigation with prejudice (meaning it's over, permanently). BioMarin releases all pre-settlement infringement claims and promises not to sue again over these patents. Ascendis agrees not to challenge BioMarin's patent rights going forward. There's also a mutual "stay out of each other's regulatory lane" clause, which prevents either company from interfering with the other's regulatory filings.
It's a clean break with a built-in revenue share. Think of it like a messy divorce that ends with a structured alimony agreement: nobody's thrilled, but everyone can move on.
The Math That Matters
Let's talk about what a 20% royalty actually means in practice.
If YUVIWEL becomes a major achondroplasia treatment (and its clinical profile suggests it could), we're talking about potentially hundreds of millions in annual sales across the U.S. alone. A fifth of that going to BioMarin is a meaningful revenue stream, essentially free money for a patent license rather than a product BioMarin has to manufacture or market.
For Ascendis, 80 cents on every dollar is a lot better than zero cents on every dollar, which is what an injunction would have delivered. The royalty burden will compress margins, sure. But the alternative was existential risk to the product.
The May 2030 expiration date is also worth noting. That gives Ascendis roughly four years of royalty payments before it can keep the full economics of YUVIWEL sales. Not forever, but not trivial either.
Why BioMarin Is Smiling
BioMarin plays this brilliantly from a portfolio strategy perspective.
The company already dominates the achondroplasia market with Voxzogo and has been aggressively expanding that franchise. Phase 3 data in hypochondroplasia was also anticipated around the same time. BioMarin is even studying Voxzogo in idiopathic short stature and Noonan syndrome, though studies in Turner syndrome and SHOX deficiency have been discontinued due to safety concerns.
On top of all that, BioMarin has BMN 333 in the pipeline, a next-generation CNP therapy designed to deliver even longer-lasting exposure than current options. Phase 1 data reportedly showed it exceeded targeted free CNP levels, which positions it as a potential second-wave achondroplasia drug.
So BioMarin gets to collect royalties from its competitor's sales while simultaneously developing the next product designed to outcompete that same competitor. That's like charging rent to the restaurant that opened next to yours while you're renovating your kitchen for a Michelin-star menu.
What This Means for Ascendis
Ascendis isn't exactly losing here; it's paying for certainty.
The company's TransCon platform is the engine behind its entire business. Beyond YUVIWEL, Ascendis has licensed TransCon technology to Novo Nordisk for metabolic and cardiovascular diseases (a deal worth up to $285 million for the lead program alone). It has granted exclusive rights to VISEN Pharmaceuticals for TransCon products in Greater China, and to Eyconis for ophthalmology globally. Ascendis retains significant equity stakes in both VISEN (39%) and Eyconis (41%).
The BioMarin settlement removes the biggest legal threat to Ascendis's most important near-term commercial asset. Investors who feared an injunction or protracted litigation can now model YUVIWEL revenue with much more confidence, even after accounting for royalties.
The settlement also validates YUVIWEL as a legitimate product in a competitive market. BioMarin essentially acknowledged, through the license structure, that this drug is going to generate enough sales to be worth a royalty deal rather than a fight to the death.
The Bigger Picture for Rare Disease
This settlement highlights a pattern that's becoming more common in rare disease: compete, litigate, then cooperate.
When markets are small (achondroplasia affects roughly 1 in 15,000 to 40,000 births worldwide), companies can't afford to spend years in court while patients wait. The legal fees alone can rival the revenue at stake. Both Ascendis and BioMarin clearly decided that a structured coexistence was better than mutually assured destruction.
The cooperative framework also includes provisions that could matter if YUVIWEL expands into new indications. The license covers "all current and potential indications," which means Ascendis doesn't need to renegotiate if it pursues hypochondroplasia or combination therapies. That kind of forward-looking language suggests both companies expect this market to grow.
What to Watch Next
Three things will determine whether this deal ages well:
First, YUVIWEL's commercial launch trajectory. How quickly can Ascendis ramp prescriptions? The faster sales grow, the happier BioMarin is (royalties) and the more Ascendis proves the drug's value despite the margin hit.
Second, BioMarin's Voxzogo expansion data. If Voxzogo wins approvals in hypochondroplasia and other skeletal conditions, the competitive dynamic shifts. YUVIWEL's once-weekly convenience advantage matters most in a market where there aren't many alternatives.
Third, BMN 333's clinical progress. If BioMarin's next-generation CNP drug delivers on its early promise, the royalty deal becomes less important than the pipeline threat. Ascendis would then be paying royalties on a product that's facing a potentially superior competitor from the same company collecting those royalties.
For now, the handshake is done. The lawyers can go home. And two rare disease companies can get back to the thing that actually matters: helping kids grow.
Deals & M&A
5 min read
Lilly Just Spent $2.88 Billion to Teach Your Body to Eat Its Own Antibodies
Eli Lilly is spending $2.88 billion to acquire Merida Biosciences and its technology that selectively destroys disease-causing antibodies while leaving the rest of your immune system alone. It's the company's biggest bet yet that autoimmune disease will be its next blockbuster franchise.
